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Summary Objective: To assess the impact on quality of life from upper airway
symptoms in chronic obstructive pulmonary disease (COPD).
Methods: Sixty-five patients with moderate-to-severe COPD were studied using
the 20-item Sino-Nasal Outcome Test (SNOT-20) questionnaire, a validated disease-
specific health-related quality of life tool for the assessment of rhinosinusitis.
Patients also completed the St. George’s Respiratory Questionnaire (SGRQ).
Results: Eighty-eight percent of patients experienced nasal symptoms on most
days of the week, most commonly rhinorrhoea. The mean SNOT-20 score of 1.24
demonstrates that nasal symptoms cause impairment to quality of life. The SNOT-20
score correlated with the number of chronic nasal symptoms (rho¼ 0.51, Po0.01):
the more daily nasal symptoms experienced, the greater the impact on health
status. There was no significant correlation between SNOT-20 and SGRQ (r¼ 0.21,
P¼ 0.09) suggesting that both upper and lower airway symptoms contribute to the
total quality of life burden.
Conclusions: This is the first study to report on upper airway involvement in well
characterised COPD patients using a previously validated assessment tool. Upper
airway symptoms are frequent in these patients and cause impairment to the quality
of life. These effects may not be detected using currently available quality of life
tools that focus on lower respiratory tract symptoms.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
The upper and lower airways are in anatomical
continuity, function as a single unit, and respond in
similar ways to noxious stimuli.1 In contrast to
asthma where there is considerable work describing
the relationship with rhinitis,2 little has been
published on upper airway involvement in patients
with chronic obstructive pulmonary disease
(COPD). This is despite the high prevalence of
upper airway symptoms in COPD. Montnemery and
colleagues study of 392 subjects aged between 20
and 59 years who self-reported chronic bronchitis
or emphysema found that 40% experienced recur-
rent or persistent nasal symptoms.3 We have
subsequently shown that in a well-characterised
group of patients with moderate-to-severe COPD
the prevalence rate of chronic nasal symptoms is
even higher at 75%.4
Assessing patients objectively for upper airway
involvement is difficult because the correlation
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findings is poor.5 A US task force on rhinosinusitis
has therefore recommended the use of a symptom-
based approach to assess upper airway pathology.5
A number of tools have been developed to quantify
upper airway involvement, including the 20-item
sino-nasal outcome test (SNOT-20).6 The SNOT-20 is
a validated, disease-specific, health-related quality
of life questionnaire that has widespread accep-
tance in the United Kingdom following the adoption
of a variant for a recent national audit of
otorhinolaryngology practice. Scores in normal
control patients have been previously published.6
The purpose of this study was to assess the
impact on quality of life from upper airway
symptoms in a population with COPD using the
SNOT-20 questionnaire, and to relate this to health




Sixty-five patients were recruited at random from
the East London (UK) COPD study. This rolling
cohort of around 100 patients have well-charac-
terised COPD and are followed prospectively,
attending for regular review and filling in daily
diary cards of peak expiratory flow rate and
increase in symptoms.7 Patients record change in
the ‘major’ symptoms of dyspnoea, sputum volume
and sputum purulence, and the ‘minor’ symptoms
of cough, wheeze, sore-throat, fever and those of
the common cold. An exacerbation is defined, as in
our previous work, as an increase in two or more
symptoms, at least one of which must be a major
symptom, for a minimum of two consecutive days.
This allows calculation of exacerbation frequency
according to our previous methodology.7 Patients
are dichotomised at the median exacerbation
frequency value into ‘frequent’ and ‘infrequent’
exacerbators. Entry criteria to the study were a
forced expiratory volume in 1 s (FEV1) of less than
70% predicted for age, sex, ethnicity and height; a
b2-agonist reversibility on predicted FEV1 of less
than 15% and/or 200ml; and airflow obstruction as
demonstrated by a post-bronchodilator FEV1 to
forced vital capacity (FVC) ratio of less than 70%.
Patients with a history of asthma, clinically
significant bronchiectasis, bronchogenic carcinoma
or other relevant respiratory disease were ex-
cluded. None of the patients gave a history of
atopy. No patients were taking regular intra-nasal
therapy. Seven of the 65 (11%) patients had
previously seen a specialist with a diagnosis of
rhinosinusitis. All participants gave informed con-
sent and the study has approval from the East
London and The City Research Ethics Committee.
Protocol
The SNOT-20 and SGRQ were self-administered
during a clinic visit between October 2002 and
April 2003, at a time when clinically stable and at
least 6 weeks following the last exacerbation. In
addition, the presence or absence on most days of
the week of the five principal upper -airway
symptoms rhinorrhoea, post-nasal drip, decreased
sense of smell, blocked nose and sneezing were
binary coded and summed to give a nasal score
between 0 and 5.
SNOT-20 questionnaire
The SNOT-20 questionnaire6 comprises 20 items
that assess both the symptoms of rhinosinusitis and
the impact that these have on health status. Each
item is graded on a 5-point scale from ‘no problem’
to ‘problem as bad as it can be’ and the resultant
sum is divided by 20 to yield a SNOT-20 score
between 0 and 5. A higher score therefore
represents a worse impairment to health status
due to upper airway symptoms. A control popula-
tion without rhinosinusitis studied during validation
of the questionnaire had a mean score of 0.6.6
Statistical analysis
Data was analysed using SPSS for Windows version
10.0 (SPSS Inc, Chicago, Illinois, USA). Data with
normal distribution is described by mean and
standard deviation (SD), skewed data by median
and interquartile range (IQR). Pearson’s correlation
was used to assess the relationship between data
with normal distribution; Spearman’s rank correla-
tion was used when one or both variables were
skewed.
Results
The 65 subjects in this study had a mean (SD) age of
69.1 (6.5) years, FEV1 0.93 (0.35) l and FEV1%
predicted 42.6 (14.8)%; 37 were male, 23 were
current smokers and all the remainder were ex-
smokers. The median (IQR) exacerbation frequency
was 2.7 (1.7–3.9) per year.
Fifty-seven of the 65 patients (88%) experienced
at least one nasal symptom on most days of the
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week. This was most commonly rhinorrhoea (34/
65), blocked nose (33/65) or sneezing (33/65).
Post-nasal drip (28/65) and decreased sense of
smell (20/65) were less common. The relationships
between nasal score, SNOT-20 and SGRQ are
reported in Fig. 1.
The nasal score correlated significantly
(rho¼ 0.51, Po0.01) with the SNOT-20 result as
illustrated in Fig. 2. There was no significant
correlation between the SNOT-20 and SGRQ total
score (r¼ 0.21, P¼ 0.09), or between the SNOT-20
and individual impact, activity or symptom domains
of the SGRQ. There were no significant relation-
ships between the nasal score or SNOT-20 and the
variables age, sex, FEV1, current smoking status or
exacerbation frequency. There was also no differ-
ence in nasal or SNOT-20 scores between patients
who had and had not been previously diagnosed
with rhinosinusitis. A significant relationship was
demonstrated between SGRQ and exacerbation
frequency with frequent exacerbators having a
worse quality of life (rho¼ 0.424, Po0.001).
Discussion
This study confirms the high prevalence of chronic
nasal symptoms in COPD: 88% of patients with
moderate to severe COPD in this cohort were
affected. The most common chronic upper airway
symptom is rhinorrhoea. Nasal symptoms result in
impaired quality of life as assessed by the SNOT-20
questionnaire. The more daily nasal symptoms
experienced, the greater the impairment to quality
of life.
The mean SNOT-20 score of 1.24 is less than that
demonstrated in a population of patients with
rhinosinusitis, studied during validation of the
SNOT-20 questionnaire, who had a mean score of
1.9.6 Therefore, while nasal symptoms are highly
prevalent in COPD they seem to cause less impair-
ment to health status than in patients with
rhinosinusitis alone. We postulate that because
patients with COPD also have significant lower
respiratory tract symptoms that are known to
affect quality of life,8 the lower respiratory tract
symptoms mask some of the effect of the upper
airway symptoms. We note that the mean SNOT-20
score in COPD patients without daily nasal symp-
toms was 0.6, identical to that previously found in
normal control patients.6 This suggests validity of
the questionnaire to assess upper airway involve-
ment in COPD.
The absence of a relationship between current
smoking status and the nasal or SNOT-20 scores is
interesting given that active smoking is known to be
associated with symptoms of chronic rhinitis.9 The
pathogenesis of upper airway symptoms in COPD is
poorly understood but it is known that there is
continuing lower airway inflammation in COPD even
after smoking cessation.10 The finding of similar
SNOT-20 scores in both current and ex-smokers
suggests that there may also be ongoing upper
airway inflammation in these patients. The me-
chanisms underlying upper airway involvement in
COPD therefore deserve further study.
The SNOT-20 and SGRQ are both validated,
disease-specific health-related quality of life ques-
tionnaires.6,8 One explanation for the poor correla-
tion between these two scores would be that
the total quality of life burden in COPD has compo-
nents due independently to both upper and lower
airway involvement. This has not been previously
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Figure 1 Relationship between nasal score and mean
SNOT-20 (circles) and SGRQ (triangles).
Figure 2 Correlation between nasal score and SNOT-20.
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reported. Tools such as the SGRQ that are designed
to assess lower airway symptoms may therefore
miss effects on quality of life due to upper airway
involvement. Factors that are known to affect
quality of life in COPD include FEV1,
8 Medical
Research Council (MRC) dyspnoea scale11 and
exacerbation frequency.12 This study confirms our
previous finding of greater impairment to health
status in patients who have higher exacerbation
frequency.12 We suggest that upper airway symp-
toms also contribute to impaired health status in
patients with COPD. This data raises the hypothesis
that novel therapeutic strategies directed towards
the upper airway may have beneficial effects on
health status in these patients.
Despite the reported poor correlation between
symptoms, clinical findings and radiological disease
in rhinosinusitis, the simple 5-point nasal score
correlated well with the more complex SNOT-20
questionnaire. We therefore believe that the nasal
score gives a practical, rapid and useful indication
of upper airway involvement in these patients.
This is the first study to report on upper airway
involvement in a well-characterised cohort of COPD
patients using a previously validated assessment
tool. We have confirmed that nasal symptoms are
common in COPD and gone on to demonstrate a
resultant impact on health status, independent
from that due to lower airway symptoms. Given the
high prevalence of nasal symptoms in COPD and the
subsequent effect on quality of life, upper airway
involvement in COPD deserves further attention.
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